Loading...
KYTX logo

Kyverna Therapeutics, Inc.NasdaqGS:KYTX Stock Report

Market Cap US$479.4m
Share Price
US$8.04
US$35
77.0% undervalued intrinsic discount
1Y176.3%
7D5.0%
1D
Portfolio Value
​
View

Kyverna Therapeutics, Inc.

NasdaqGS:KYTX Stock Report

Market Cap: US$479.4m

Kyverna Therapeutics (KYTX) Stock Overview

A late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. More details

KYTX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Revenue is forecast to grow 64.22% per year

Analysts in good agreement that stock price will rise by 278.1%

Risk Analysis

Earnings are forecast to decline by an average of 6.6% per year for the next 3 years

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years


KYTX Community Fair Values

Create Narrative

See what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.

Top Community Narratives

View all narratives

Kyverna Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Kyverna Therapeutics
Historical stock prices
Current Share PriceUS$8.04
52 Week HighUS$13.67
52 Week LowUS$2.52
Beta1.96
1 Month Change-5.85%
3 Month Change-5.85%
1 Year Change176.29%
3 Year Changen/a
5 Year Changen/a
Change since IPO-73.20%

Recent News & Updates

Seeking Alpha • Apr 21

Kyverna Therapeutics Positive Phase 2 Readout: Deep Responses, But Very Small Sample

Summary Kyverna Therapeutics (KYTX) reported robust early Phase 2 miv-cel data in gMG, showing 100% response rates and deep, durable clinical improvements. KYTX’s miv-cel offers rapid onset, potential for treatment-free remission, and a differentiated safety profile, but results are based on a small, uncontrolled cohort. The market discounts KYTX due to execution risk, small sample size, and anticipated dilution, despite a modest $350M enterprise value and $279M cash runway. If Phase 3 validates these findings, miv-cel could redefine gMG treatment and expand into a multi-indication autoimmune platform, positioning today’s valuation as an early entry. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Apr 21

Kyverna Therapeutics Positive Phase 2 Readout: Deep Responses, But Very Small Sample

Summary Kyverna Therapeutics (KYTX) reported robust early Phase 2 miv-cel data in gMG, showing 100% response rates and deep, durable clinical improvements. KYTX’s miv-cel offers rapid onset, potential for treatment-free remission, and a differentiated safety profile, but results are based on a small, uncontrolled cohort. The market discounts KYTX due to execution risk, small sample size, and anticipated dilution, despite a modest $350M enterprise value and $279M cash runway. If Phase 3 validates these findings, miv-cel could redefine gMG treatment and expand into a multi-indication autoimmune platform, positioning today’s valuation as an early entry. Read the full article on Seeking Alpha
Analysis Article • Nov 03

We're Keeping An Eye On Kyverna Therapeutics' (NASDAQ:KYTX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Mar 21

Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025

Summary Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half of 2025. The global Myasthenia Gravis market is expected to generate sales of $6.7 billion by 2032. Release of topline data from phase 2 KYSA-8 study, using KYV-101 for the treatment of patients with Stiff Person Syndrome, expected in 1st half of 2026. The company is developing differentiated CD-19 CAR-T with a fully-human construct to reduce safety incidents of CRS and ICANS for starters; Plus, incorporate greater B-cell depletion and immune reset. Read the full article on Seeking Alpha
Seeking Alpha • Dec 12

Kyverna Therapeutics: CAR T-Cells Trying To Impact Inflammatory Disorders

Summary Kyverna Therapeutics is pioneering engineered cell therapy for inflammatory disorders, leveraging CAR-T cell therapy's success in B-cell cancers. KYTX holds $104.7M in cash and $216.9M in marketable securities, with a quarterly net loss of $34.5M. The company has a cash runway of 9-10 quarters but faces high cash burn and potential dilution risks in the not-too-distant future. Investors should hold off for now as the programs and the field at large matures. Read the full article on Seeking Alpha
Analysis Article • Nov 17

Here's Why We're Watching Kyverna Therapeutics' (NASDAQ:KYTX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Aug 08

We're Not Very Worried About Kyverna Therapeutics' (NASDAQ:KYTX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

KYTXUS BiotechsUS Market
7D5.0%4.6%2.0%
1Y176.3%30.5%23.3%

Return vs Industry: KYTX exceeded the US Biotechs industry which returned 30.9% over the past year.

Return vs Market: KYTX exceeded the US Market which returned 25.5% over the past year.

Price Volatility

Is KYTX's price volatile compared to industry and market?
KYTX volatility
KYTX Average Weekly Movement11.1%
Biotechs Industry Average Movement10.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: KYTX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: KYTX's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2018129Warner Biddlekyvernatx.com

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate.

Kyverna Therapeutics, Inc. Fundamentals Summary

How do Kyverna Therapeutics's earnings and revenue compare to its market cap?
KYTX fundamental statistics
Market capUS$479.40m
Earnings (TTM)-US$156.40m
Revenue (TTM)n/a
0.0x
P/S Ratio
-3.1x
P/E Ratio

Is KYTX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KYTX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$126.36m
Gross Profit-US$126.36m
Other ExpensesUS$30.04m
Earnings-US$156.40m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-2.58
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio12.7%

How did KYTX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/17 03:22
End of Day Share Price 2026/06/17 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kyverna Therapeutics, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mitchell KapoorH.C. Wainwright & Co.
Lut Ming ChengJ.P. Morgan
Thomas SmithLeerink Partners LLC